Form 4: Aprea Therapeutics Executive Acquires Shares and Stock Options

John P. Hamill, SrVP/CFO/Prin Fin & Acct Ofcr of Aprea Therapeutics, acquired shares and stock options on March 27, 2025.

Summary

• On March 27, 2025, John P. Hamill, SrVP/CFO/Prin Fin & Acct Ofcr of Aprea Therapeutics, acquired 3,365 shares of common stock.
• These shares represent restricted stock units that will vest in three equal annual installments starting March 27, 2026, contingent upon continued employment.
• Hamill also acquired 13,460 stock options with an exercise price of $2.20.
• 25% of these options vest on March 27, 2026, with the remainder vesting ratably over the next 36 months, also contingent upon continued employment.
• Following these transactions, Hamill beneficially owns 22,733 shares of common stock and 13,460 stock options.

Sentiment

Score: 6

Explanation: Neutral sentiment. It's a standard Form 4 filing indicating executive compensation. The acquisition of shares and options could be seen as a positive sign, but it's not overwhelmingly bullish.

Positives

• The acquisition of shares and options by a senior executive could be interpreted as a sign of confidence in the company's future prospects.

Future Outlook

The restricted stock units and stock options are subject to continued employment and may accelerate under certain conditions, suggesting a focus on retaining the executive.

Industry Context

Form 4 filings are routine disclosures of insider transactions, providing transparency into the actions of company executives. These filings are closely watched by investors for signals about management's view of the company's prospects.

Stakeholder Impact

• Shareholders may view the executive's increased stake in the company positively.
• The vesting conditions tied to continued employment incentivize the executive to remain with the company.

Key Dates

Keywords

Aprea Therapeutics, John P. Hamill, Form 4, Stock Options, Restricted Stock Units, Beneficial Ownership, Insider Trading